At a Glance

Lithium carbonate is FDA-approved for bipolar disorder at therapeutic doses (900-1800mg daily). Low-dose lithium (5-20mg daily) and lithium orotate (sold as dietary supplement in the US at sub-therapeutic doses) lack regulatory pathways. Neuroprotective potential is significant but unproven in human trials.

What It Is

Lithium is a naturally occurring trace mineral and FDA-approved psychiatric medication. Low-dose lithium and lithium orotate are used off-label for neuroprotection and longevity, distinct from therapeutic-dose psychiatric treatment. Regulatory classification varies: therapeutic lithium carbonate is a drug; lithium orotate is often sold as a dietary supplement.

How It Works

At therapeutic psychiatric doses, lithium inhibits inositol monophosphatase (IMPase) and glycogen synthase kinase-3 (GSK-3), affecting inositol signaling and neurotransmission. At low doses, it may provide neuroprotective effects through GSK-3 inhibition, anti-apoptotic signaling, and anti-inflammatory mechanisms, though these effects are incompletely understood.

Key Benefits

  • Potential neuroprotection and cognitive enhancement at low doses (based primarily on preclinical and epidemiological data)
  • GSK-3 inhibition may reduce tau pathology and neuroinflammation
  • Possible mood and cognitive benefits beyond psychiatric indications
  • Relatively inexpensive compared to other neuroprotective compounds
  • Extensive safety data at therapeutic psychiatric doses

Who It's For

  • Individuals seeking neuroprotective support for cognitive aging or mild cognitive decline
  • Those interested in tau pathology reduction in aging-related neurodegeneration
  • NOT suitable for those with significant kidney disease or untreated thyroid dysfunction. Use with caution in diabetes (may affect glucose metabolism and hydration status)
  • Requires baseline and periodic renal function and thyroid monitoring

Typical Use

Low-dose neuroprotective lithium: 5-20mg elemental lithium daily, typically as lithium orotate (which is approximately 4.3% elemental lithium by weight). Therapeutic psychiatric lithium: 900-1800mg daily (requiring blood level monitoring 0.6-1.2 mEq/L). Neuroprotective protocols lack established dosing guidelines.

Important Safety Information

  • Regulatory classification ambiguous: lithium orotate sold as supplement but contains active lithium
  • Therapeutic lithium requires blood level monitoring; low-dose protocols often omit this
  • Tremor, polyuria, and polydipsia reported even at low doses in sensitive individuals
  • Contraindicated in kidney disease, dehydration, and certain cardiac conditions, and pregnancy (teratogenic — Pregnancy Category D, associated with Ebstein’s anomaly). Risk of nephrogenic diabetes insipidus with chronic use. Serotonin syndrome risk when combined with SSRIs/serotonergic drugs
  • Known clinically significant drug interactions with diuretics (especially thiazides), NSAIDs, and ACE inhibitors that can cause dangerous lithium toxicity

Global Regulatory Status

Note: No regulatory distinction between low-dose and therapeutic lithium in any jurisdiction. Lithium orotate regulatory status varies: US treats it as dietary supplement; other jurisdictions may classify differently. Neuroprotective low-dose protocols lack established dosing and safety data.

The Bottom Line

Low-dose lithium has compelling neuroprotective mechanisms and growing interest in aging research. However, it exists in regulatory limbo: lithium carbonate is an approved drug but therapeutic indications are psychiatric, while lithium orotate supplements are largely unregulated. Use requires baseline and periodic kidney and thyroid function assessment, and informed consent about unproven efficacy at low doses.

This guide is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any supplement or medication.